DUBLIN--(BUSINESS WIRE)--The "U.S. Atherectomy Devices Market Size, Share & Trends Analysis Report By Type (Laser, Directional, Rotational, Orbital), By End Use (Office-based Labs, Out-patient Facility, In-patient Facility), And Segment Forecasts, 2019-2025" report has been added to ResearchAndMarkets.com's offering.
The U.S. atherectomy devices market size is expected to reach USD 626.1 million by 2025 expanding at a CAGR of 6.6%.
The regional market is expected to witness lucrative growth due to the rising prevalence of target diseases and preference for endovascular procedures. Moreover, the rising demand for the minimally invasive procedure will boost market growth. Such procedures are less painful and allow quicker recovery than invasive procedures.
Other advantages, such as higher patient satisfaction owing to fewer incision wounds, few post-surgical complications, and low mortality rates, are also driving the atherectomy devices market growth.
Technological advancements allowing early diagnosis are also likely to augment the market growth in the near future. For instance, in January 2017, Medtronic received CE mark approval for HawkOne directional atherectomy system for treating patients suffering from Peripheral Artery Disease (PAD).
Further key findings from the study suggest:
- Adoption of atherectomy increased sharply in the past due to increased reimbursement for the procedure. According to Elsevier Inc., there was a rise in atherectomy volume for Medicare beneficiaries to 76% in 2011-2015
- Directional atherectomy devices accounted for the largest share of the market in 2017 as the device exhibited 95% successful removal of lesions and 94% of patients did not exhibit adverse effects
- Office-Based Labs (OBLs) is anticipated to be the fastest-growing segment in the forecast period due to a greater number of Peripheral Vascular Interventional (PVI) procedures being performed in this setting
- In addition, a lesser number of complications and follow-up procedures lowers the cost and increases the adoption of new technologies delivering better health outcomes, which is anticipated to propel the market growth in the coming years
- Several ongoing trials and their positive results facilitate penetration of novel technologies. For instance, in March 2017, Cardiovascular Systems, Inc. enrolled for its latest clinical trial, ECLIPSE, which was perceived to be the largest trial conducted to study coronary atherectomy
- Some of the key companies are Spectranetics Corp.; Boston Scientific Corp.; Cardinal Health, Inc.; Straub Medical AG; Terumo Medical Corp.; Cardiovascular Systems, Inc.; Medtronic PLC; Avinger, Inc.; St. Jude Medical, Inc.
Key Topics Covered
Chapter 1 Research Methodology
1.1 Information Procurement
1.2 Data Analysis
Chapter 2 Executive Summary
2.1 Market Snapshot
Chapter 3 Market Variables, Trends & Scope
3.1 Market Segmentation and Scope
3.1.1 Market driver analysis
3.1.1.1 Increasing prevalence of target diseases
3.1.1.2 Preference for minimally invasive procedures
3.1.2 Market restraint analysis
3.1.2.1 Lack of level 1 evidence for atherectomy
3.1.2.2 Lack of technical training for the procedure
3.1.2.3 Significant adoption of alternative therapies
3.2 Penetration & Growth Prospects Mapping
3.3 U.S. Atherectomy Devices Market - PESTLE Analysis
3.4 Industry Analysis - Porter's
3.5 U.S. Atherectomy Devices: Regulatory Scenario
3.6 U.S. Atherectomy Devices Market: Reimbursement Scenario
3.7 Key Clinical Trials & Studies
3.7.1 Opinions/Views on Key Clinical Trials and Their Impact on the Market and Customer
3.8 U.S. Peripheral Atherectomy: Number of Procedures
Chapter 4 U.S. Atherectomy Devices Market: Type Estimates & Trend Analysis
4.1 U.S. Atherectomy Devices Market: Type Movement Analysis
4.2 Directional Atherectomy Devices
4.3 Rotational Atherectomy Devices
4.4 Orbital Atherectomy Devices
4.5 Laser Atherectomy Devices
Chapter 5 U.S. Atherectomy Devices Market: End-Use Estimates & Trend Analysis
5.1 U.S. Atherectomy Devices Market: End-Use Movement Analysis
5.2 In-Patient Facility
5.3 Office-Based Labs (OBLs)
5.4 Out-Patient facility
Chapter 6 Competitive Landscape
6.1 Strategy Framework
6.2 Competitive Landscape: Market Position Analysis
6.3 Company Profiles
6.3.1 Boston Scientific Corporation
6.3.1.1 Company overview
6.3.1.2 Financial performance
6.3.1.3 SWOT analysis
6.3.1.4 Product benchmarking
6.3.1.5 Strategic initiatives
6.3.2 Cardiovascular Systems, Inc.
6.3.3 Medtronic
6.3.4 Spectranetics
6.3.5 Avinger
6.3.6 St. Jude Medical
6.3.7 Cardinal Health (Cordis)
6.3.8 Terumo Medical Corporation
Chapter 7 Recommendations
7.1 KOL Views
7.2 Recommendations
For more information about this report visit https://www.researchandmarkets.com/research/x9n5v6/united_states?w=4
